Zonisamide

Routes
Oral (PO)
Half-Life (t½)
PO: 63h
Formula
C8H8N2O3S
Molecular Weight
212.23 g/mol
PubChem CID
5734
Aliases
Zonegran

Pharmacological Mechanism

Sulfonamide antiseizure — Na+ + T-type Ca²⁺ channel blocker, weak carbonic anhydrase inhibition. Adjunct for partial seizures + off-label migraine prophylaxis + weight-loss adjunct (Qsymia precursor mechanistic relative).

Half-Life & Elimination Curve (PO: 63h)

100%50%25%12.5%0%0h0×t½63h1×t½5.3d2×t½7.9d3×t½10.5d4×t½13.1d5×t½0×t½ (0h): 100% remaining (~1.01 mg/L)1×t½ (63h): 50% remaining (~0.506 mg/L)2×t½ (5.3d): 25% remaining (~0.253 mg/L)3×t½ (7.9d): 12.5% remaining (~0.126 mg/L)4×t½ (10.5d): 6.3% remaining (~63.2 µg/L)5×t½ (13.1d): 3.1% remaining (~31.6 µg/L)
Plasma (PO)t½ Decay (63h)Effect Site (ke0)
  • 0×t½0h100% (1.01 mg/L)
  • 1×t½63h50% (0.506 mg/L)
  • 2×t½5.3d25% (0.253 mg/L)
  • 3×t½7.9d12.5% (0.126 mg/L)
  • 4×t½10.5d6.3% (63.2 µg/L)
  • 5×t½13.1d3.1% (31.6 µg/L)
Elimination t½63h (PO)
Rate Constant (ke)0.011 h⁻¹
Time to Peak (Tmax)57.3h
Est. Peak (Cmax)1.01 mg/L
Clearance (CL)1.1 L/h
97% Washout (5×t½)13.1d

Dosing Guidelines

Pharmacokinetic Parameters

Receptor Binding & Occupancy

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References